Abstracts tagged "Vasculitis"

Abstract Number: 0757 • ACR Convergence 2024
Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis
Anna Kernder¹, Lena Noack¹, Adina Morar¹, Lara Burg², Torsten Lowin¹, Dennis Bleck¹, matthias schneider¹, Jörg Distler³, Georg Pongratz⁴ and Valentin S. Schäfer⁵, ¹Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Düsseldorf, Germany, ²Department of Rheumatology and Clinical Immunology, Clinic of Internal Medicine III, University Hospital of Bonn, Germany, Bonn, Germany, ³Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, ⁴Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Regensburg, Germany, ⁵University Hospital Bonn, Bonn, Germany
Background/Purpose: The immunopathogenesis of giant cell arteritis (GCA) remains unclear. It is known that monocytes are recruited from peripheral blood, infiltrate the vessel wall, and…
Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 1620 • ACR Convergence 2024
Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse
Simon Petzinna¹, Jim Küppers², Benedikt Schemmer², Anna Kernder³, Claus Juergen Bauer¹, Pantelis Karakostas¹, Denada Bruci³, Adina Morar³, Anja Winklbauer², Markus Essler² and Valentin S. Schäfer², ¹Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, Bonn, Germany, ²University Hospital Bonn, Bonn, Germany, ³University Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
Background/Purpose: Vascular adhesion protein-1 (VAP-1) is a transmembrane adhesion molecule with oxidative deamination functionality, which is expressed in vascular smooth muscle cells and endothelial cells.…
Abstract Number: 1896 • ACR Convergence 2024
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Priyanka Chandratre¹, Joht Chandan², Ben Hammond³, Rasiah Thayakaran³, Samuel Cusworth³, Nicola Adderley³ and Deva Situnayake⁴, ¹The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, ²Institute of Applied Health Research, Birmingham, United Kingdom, ³Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁴Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
Abstract Number: 2498 • ACR Convergence 2024
The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis
Veronica Pulito-Cueto¹, Joao Carlos Batista-Liz¹, Laura Carmen Terron², Iván Fernández Rengel³, María Sebastián Mora-Gil⁴, María Teresa Leonardo⁵, Ana Peñalba⁵, Luis Martín-Penagos⁶, Lara Belmar-Vega⁷, Cristina Gomez-Fernandez⁸, Ligia Gabrie-Rodriguez⁹, Rafael Gálvez Sánchez⁹, Luis Caminal-Montero¹⁰, Ana Turrion Nieves¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Belén Sevilla-Pérez¹⁴, José Luis Callejas¹⁵, Eduardo Andrés-León², Javier Martin¹⁶, Ana María Marquez¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, ³Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, ⁴Immunopathology Group, IDIVAL, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, ⁸Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁵Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁶Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ¹⁷Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers…
Abstract Number: 2522 • ACR Convergence 2024
Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Kerem Abacar¹, Ayşe Elif Boncukcuoğlu¹, Aysun Aksoy², Derya Kocakaya¹, Çagatay Cimşit¹, Haner Direskeneli³ and Fatma Alibaz Öner³, ¹Marmara University, istanbul, Turkey, ²Alaaddin Keykubat University, Antalya, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
Abstract Number: 0760 • ACR Convergence 2024
A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis
Kevin Chevalier¹, Léa Dionet¹, Paul Breillat¹, Margot Poux¹, Julien Dang¹, Benoit Terris², Patrick Bruneval³, Luc Mouthon⁴, Olivia Lenoir¹, Tharaux Pierre-Louis¹ and Benjamin Terrier⁵, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ³Department of Pathology, Hôpital Européen Georges Pompidou, GHU Paris Centre, AP-HP, Université Paris Cité, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis affecting large vessels. The role of macrophages and vascular smooth muscle cells (VSMC) appears to be…
Abstract Number: 1106 • ACR Convergence 2024
Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Clara Moriano⁴, Javier Narvaez-García⁵, Vicente Aldasoro⁶, Olga Maíz Alonso⁷, Iñigo Hernández-Rodríguez⁸, Paloma Vela-Casasempere⁹, Susana Romero Yuste¹⁰, Eugenio De Miguel¹¹, Eva Galindez-Agirregoikoa¹², Jesus C. Fernandez-López¹³, ivan Ferraz-Amaro¹⁴, Julio Sánchez-Martín¹⁵, José Luis Callejas¹⁶, Patricia Moya Albarado¹⁷, Cristina Campos Fernández¹⁸, Fernando Lopez-Gutierrez¹⁹, Santos Castañeda²⁰ and Ricardo Blanco-Alonso²¹, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital León, LEON, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ⁸Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario La Paz, Madrid, Spain, ¹²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹³11Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, ¹⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁷Hospital de San Pau, Barcelona, Spain, ¹⁸Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²⁰Hospital Universitario de la Princesa, Madrid, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
Abstract Number: 1621 • ACR Convergence 2024
Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
Ufuoma Mamoh¹, Soziema Salia¹, Joan Morny², Jesse Odion³, Elem Ewuru⁴, Precious Onobraigho⁵, Eugene Omoike⁵, Oyidia Ijioma⁶, Osaruese Ezomo⁷ and Ehizogie Edigin⁸, ¹Medstar Union Memorial Hospital, Baltimore, MD, ²Piedmont Athens Regional Medical Center, Athens, GA, ³Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom, ⁴Acute and Emergency Care United Kingdom Medway Maritime Hospital, Gillingham, ⁵College of Medicine, University of Benin, Benin, Nigeria, ⁶Department of Clinical Psychiatry, University of South Wales, Wales, United Kingdom, ⁷Department of Gastroenterology, Spire Manchester Hospital, Manchester, United Kingdom, ⁸The University of Texas Health Science Center, houston, TX
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis, typically affecting young children, and is the leading cause of acquired heart disease in children in developed…
Abstract Number: 1962 • ACR Convergence 2024
Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis
Nouran Eshak¹, Kristina Yancey², Felipe Martinez³, Lester Mertz¹, carolyn mead harvey⁴, Kenneth Warrington⁵, Matthew Koster⁵ and Megan Sullivan¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ, ³Mayo Clinic Arizona, Phoenix, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Rochester, MN
Background/Purpose: Medium vessel vasculitis (MVV), including polyarteritis nodosa (PAN), presents significant diagnostic challenges with patients frequently exhibiting non-specific systemic manifestations. While 18F-fluorodeoxyglucose PET/CT (PET/CT) is…
Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir-Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci-Yildirim⁷, Zeliha Ademoglu⁸, Elif Ediboglu⁹, Burcu Ceren Uludogan¹⁰, Nazife Sule yaşar Bile¹⁰, Timucin Kasifoglu¹¹, Servet Akar¹², Hakan Emmungil⁸, Fatos Onen⁷, Ahmet Omma¹³, Nilüfer Alpay Kanıtez¹⁴, Ayten Yazici¹⁵, Ayse Cefle¹⁵, Murat Inanc³, Kenan Aksu¹⁶, Gokhan Keser¹⁷, Haner Direskeneli¹⁸ and Fatma Alibaz Öner¹⁸, ¹Bahcesehir University Faculty of Medicine, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁸Trakya University, Edirne, Turkey, ⁹Mayo Clinic, Rochester, MN, ¹⁰Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹¹Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ¹²Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹³Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁴Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁵Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹⁶Ege University Faculty of Medicine, Izmir, Turkey, ¹⁷Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ¹⁸Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…
Abstract Number: 0726 • ACR Convergence 2024
Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
Emma Neary¹, Katie Healey², Marie Clements-Baker³, Jean-Paul Makhzoum⁴ and Arielle Mendel⁵, ¹McGill University, Montreal, QC, Canada, ²Memorial University of Newfoundland, St. John's, NL, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…
Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Helena M Amar Muñoz¹, Juan Molina-Collada¹, Isabel Castrejon², irene monjo³, Elisa Fernández-Fernández:⁴, José María Álvaro-Gracia⁵ and Eugenio De Miguel⁶, ¹Hospital General Universitario Gregorio Marañón, MADRID, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].